Accéder au contenu
Merck
Toutes les photos(1)

Documents

1479304

USP

Oseltamivir phosphate

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C16H28N2O4 ·H3PO4
Numéro CAS:
204255-11-8
Poids moléculaire :
410.40
Numéro MDL:
MFCD08059548
Code UNSPSC :
41116107
ID de substance PubChem :
329750621
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

oseltamivir

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1

InChI

1S/C16H28N2O4.H3O4P/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19;1-5(2,3)4/h9,12-15H,5-8,17H2,1-4H3,(H,18,19);(H3,1,2,3,4)/t13-,14+,15+;/m0./s1

Clé InChI

PGZUMBJQJWIWGJ-ONAKXNSWSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application


  • Neuraminidase Inhibition by Oseltamivir Phosphate: Oseltamivir phosphate′s mechanism as a neuraminidase inhibitor was highlighted in a study examining its effect on virus-neutralizing antibodies in influenza A-infected mice, demonstrating its impact on dosage and scheduling for effective flu treatment (Mikušová et al., 2022).

  • Oseltamivir Phosphate in Lung Cancer Research: Research explored the use of oseltamivir phosphate loaded into pegylated-Eudragit nanoparticles for lung cancer therapy, focusing on characterization, prolonged release, cytotoxicity profile, apoptosis pathways, and the anti-angiogenic effect, thereby expanding its application beyond traditional antiviral uses (Yurtdaş-Kırımlıoğlu et al., 2022).

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H317,H319,H412

Classification des risques

Aquatic Chronic 3 - Eye Irrit. 2 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Ding Yuan Oh et al.
The Journal of antimicrobial chemotherapy, 69(9), 2458-2469 (2014-05-21)
The emergence of the pandemic influenza A(H1N1)pdm09 virus in 2009 saw a significant increase in the therapeutic and prophylactic use of neuraminidase inhibitors (NAIs) to mitigate the impact of this highly transmissible virus. Prior to the pandemic, many countries stockpiled
Henju Marjuki et al.
The Journal of infectious diseases, 210(3), 435-440 (2014-02-27)
Human infections caused by avian influenza A virus type subtype H7N9 have been associated with substantial morbidity and mortality. Emergence of virus variants carrying markers of decreased susceptibility to neuraminidase inhibitors was reported. Here we show that DAS181 (Fludase), an
Henju Marjuki et al.
Journal of virology, 89(10), 5419-5426 (2015-03-06)
Human infections by avian influenza A(H7N9) virus entail substantial morbidity and mortality. Treatment of infected patients with the neuraminidase (NA) inhibitor oseltamivir was associated with emergence of viruses carrying NA substitutions. In the NA inhibition (NI) assay, R292K conferred highly
Isabelle Marois et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 29(3), 973-987 (2014-11-22)
The clinical benefits of oseltamivir (Tamiflu) are well established, but the effects of antiviral treatment on the immune response are poorly understood. By use of flow cytometric analyses and the mouse model, we thoroughly investigated the impact of such a
Aihua Song et al.
Antiviral research, 111, 60-68 (2014-09-15)
Influenza virus is a global health concern due to its unpredictable pandemic potential. Frequent mutations of surface molecules, hemagglutinin (HA) and neuraminidase (NA), contribute to low efficacy of the annual flu vaccine and therapeutic resistance to standard antiviral agents. The
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique